Loading clinical trials...

A Study of BGM-2121 in Patients With Advanced Solid Tumors | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE1

A Study of BGM-2121 in Patients With Advanced Solid Tumors

A Phase 1 First-in-human Study of BGM-2121 in Patients With Advanced Solid Tumors

NCT07346846•BioGate Precision Medicine Corp.

Summary

This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. With either gender aged ≥ 18 years,
•2. Has a confirmed diagnosis of advanced solid tumor(s),
•3. The subject has received and failed standard-of-care anti-cancer therapy
•4. Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)
•5. ...

Exclusion Criteria

•1. Has any ongoing toxicity from previous anti-cancer treatments
•2. Has signs or symptoms of end-stage organ failure, major chronic illnesses other than cancer(s)
•3. History of another primary malignancy within the last three years
•4. ...

Locations (3)

National Cheng Kung University Hospital

Tainan, Taiwan

National Taiwan University Hospital

Taipei, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan

Key Dates

Start Date

February 1, 2026

Primary Completion Date

November 1, 2027

Completion Date

December 1, 2028

Last Updated

March 2, 2026

Enrollment

ESTIMATED participants

Conditions

Advanced Solid Tumors

Interventions

BGM-2121

DRUG

Contacts

Queena Hwang

CONTACT

886-2-2517-6512 clinical@biogate.com.tw

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450

Advanced Solid Tumors CancerMSI-H Cancer

View study

RECRUITINGPHASE1

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT05719558

Advanced Solid Tumors

View study

RECRUITINGPHASE1

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 2, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of BGM-2121 in Patients With Advanced Solid Tumors

Inclusion Criteria

Exclusion Criteria

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

A Study of ASP1002 in Adults for Treatment of Solid Tumors

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)